PDL BioPharma, Inc. Debt/Assets

Debt/Assets of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Assets growth rates and interactive chart.


Highlights and Quick Summary

  • Debt/Assets for the quarter ending December 30, 2020 was 0.0% (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Debt/Assets decreased by -100.0%
  • Annual Debt/Assets for 2020 was 0.0% (a -100.0% decrease from previous year)
  • Annual Debt/Assets for 2019 was 3.81% (a -70.53% decrease from previous year)
  • Annual Debt/Assets for 2018 was 12.93% (a 36.83% increase from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Assets of PDL BioPharma, Inc.

Most recent Debt/Assetsof PDLI including historical data for past 10 years.

Interactive Chart of Debt/Assets of PDL BioPharma, Inc.

PDL BioPharma, Inc. Debt/Assets for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0% 2.59% 2.02% 0.0%
2019 3.8% 15.31% 14.43% 13.7% 3.81%
2018 12.93% 12.47% 12.78% 10.83% 12.93%
2017 9.45% 9.46% 8.76% 9.08% 9.45%
2016 19.13% 19.32% 22.19% 21.87% 19.13%
2015 22.61% 27.59% 28.1% 24.95% 22.61%
2014 28.7% 28.02% 29.77% 31.78% 28.7%
2013 0.0% 34.22% 36.32% 99.94% 0.0%
2012 110.71% 122.99% 117.3% 128.63% 110.71%
2011 117.5% 116.58% 117.0% 97.87% 117.5%
2010 124.88% 132.27% 142.93% 124.88%

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.